CS
TCRR

Credit Suisse’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Credit Suisse’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16
Closed – – 4457
2022
Q2 		$0 Buy
+16
New +$39 ﹤0.01% 4525
2021
Q4 		– Sell
-14,658
Closed -$124K – 4722
2021
Q3 		$124K Buy
14,658
+1,413
+11% +$20K ﹤0.01% 4301
2021
Q2 		$217K Sell
13,245
-11,124
-46% -$225K ﹤0.01% 4259
2021
Q1 		$538K Sell
24,369
-10,175
-29% -$277K ﹤0.01% 3722
2020
Q4 		$1.07M Buy
+34,544
New +$873K ﹤0.01% 3295

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse's TCRR Position: Q3 2022 in Review

Credit Suisse sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 16 shares.

Credit Suisse first reported a position in TCRR in Q4 2020 and held it in 5 quarters. The position peaked at $1.07M in Q4 2020. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • Credit Suisse reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 16 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022.
  • Credit Suisse first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Credit Suisse's TCR2 Therapeutics Inc. Common Stock position peaked at $1.07M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.